

In the specification: (version with markings to show changes made)

On page 8, line 41 through page 9, line 12, please make the following changes:

Antigen-presenting cells contemplated for targeting according to the present invention include, but are not limited to, monocytes, dendritic cells, macrophages, B cells and some T cells. In preferred embodiments of the invention, the characteristic determinant on the selected APC is a cell surface receptor and the targeting moiety of the APC-targeted antigen is a ligand that binds to the receptor. It is particularly preferred that the cell surface receptor be an immunomodulatory receptor. Suitable cell surface receptors include, but are not limited to, C5a receptor, IFN γ receptor, CD21 (C3d[α]) receptor, CD64 (Fc γ RI[α]) receptor, and CD23 (Fc ϵ RII[α]) receptor).

In the claims: (version with markings to show changes made)

1. (Twice amended) A molecular adjuvant for enhancing an immune response to an immunogen comprising:

a targeting ligand having binding affinity for a receptor present on [characteristic determinant of] an antigen presenting cell, said receptor being of a type that is internalized upon binding of a ligand and that transmits a signal in the antigen presenting cell that stimulates antigen processing and presentation by the antigen presenting cell, said targeting ligand being covalently linked to said immunogen, whereby binding of said molecular adjuvant to said antigen presenting cell receptor [determinant] activates said antigen presenting cell, effecting delivery of said immunogen to an antigen presenting pathway of said antigen presenting cell.

Cancel claim 2.

3. (Amended) A molecular adjuvant as claimed in claim 1 [2], wherein said targeting ligand binds specifically to a receptor selected from the group consisting of C5a receptor, IFN-gamma receptor, [CD21 (] C3d[)] receptor, [CD64 (FcγRI)] FcγRI receptor, and [CD23 (FcεRII)] FcεRII receptor.

6. (Amended) A molecular adjuvant as claimed in claim 1, comprising [a targeting ligand and an immunogen having the sequence YKQGGFLGLYSFKPMPLaR] SEQ ID NO:2.

25. (Amended) Antibodies to a selected immunogen, wherein the antibodies are produced by a method comprising the steps of:

a) immunizing an animal with an immunogenically effective amount of the molecular adjuvant of claim 1, wherein the molecular adjuvant comprises the selected immunogen; and

b) recovering the antibodies from serum of the animal [the method of claim 24].